video > Novo Nordisk Counting on New Diabetes Drug Tresiba to Dominate

Novo Nordisk Counting on New Diabetes Drug Tresiba to Dominate

Video Details
Shares of Novo Nordisk popped 5% last week after the U.S. Food and Drug Administration (FDA) approved the application for its long-acting insulin drug Tresiba ...
you may like